Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Shifts Remdesivir Distribution To Gilead As Supply Crunch Eases

Executive Summary

AmerisourceBergen will continue to serve as the sole US distributor of Veklury (remdesivir) through the end of this year and will continue to sell the the COVID-19 treatment directly to hospitals.

You may also be interested in...



Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesivir Filing

Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic. 

Remdesivir Distribution Improvements Among Goals Of US HHS Data Reporting Overhaul

Gilead’s COVID treatment will be the first product tracked in a system that could eventually help allocate vaccines and other therapeutics.

EU Approves Gilead’s Remdesivir For COVID-19 In Record Time

The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about 2,000 per treatment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel